

Name of the issuer:	Tatva Chintan Pharma Chem Limited	Last updated on	17-Jun-22
----------------------------	-----------------------------------	------------------------	-----------

1 Type of Issue (PO / FPO)	IPO
-----------------------------------	-----

2 Issue Size (Rs. Cr)	500.0
- Fresh Issue Size (Rs. Cr)	225.0
- Offer for Sale Component (Rs. Cr)	275.0
Source: Post Issue Monitoring Report	

3 Grade of Issue along with name of the rating agency	
Name	Not Applicable
Grade	Not Applicable

4 Subscription Level (Number of times)	124.52*
Source: Post Issue Monitoring Report	
*The above figure is after technical rejections and includes anchor	

5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges	
Particulars	%
(i) allotment in the issue ⁽¹⁾	10.41%
(ii) at the end of the 1st Quarter immediately after the listing of the issue	10.89%
(iii) at the end of 1st FY (March 31, 2022)	11.18%
(iv) at the end of 2nd FY (March 31, 2023)*	Not Available
(v) at the end of 3rd FY (March 31, 2024)*	Not Available
* QIB Holding not disclosed as reporting for the relevant fiscal year has not been completed.	
(1) Source: Minutes of Basis of Allotment. Includes allotment to Anchor Investors	

6 Financials of the issuer			
	(In Rs. Crore)		
Parameters (consolidated)	1st FY (March 31, 2022)	2nd FY (March 31, 2023)*	3rd FY (March 31, 2024)*
Income from operations	433.65	Not Available	Not Available
Net Profit for the period	95.87	Not Available	Not Available
Paid-up equity share capital	22.17	Not Available	Not Available
Reserves excluding revaluation reserves	450.92	Not Available	Not Available
* Financials not disclosed as reporting for the relevant fiscal year has not been completed.			

7 Trading Status in the scrip of the issuer	
Company's Equity Shares are listed on both the BSE Limited and the NSE. The Shares have not been suspended or delisted.	
Particulars	Status
(i) at the end of 1st FY (March 31, 2022)	Frequently traded
(ii) at the end of 2nd FY (March 31, 2023)*	Not Available
(iii) at the end of 3rd FY (March 31, 2024)*	Not Available
* Trading status not disclosed as the relevant fiscal year has not been completed.	

8 Change in Directors of issuer from the disclosures in the offer document		
Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2022)	-	-
(ii) at the end of 2nd FY (March 31, 2023)#	-	-
(iii) at the end of 3rd FY (March 31, 2024)*	Not Available	Not Available
# Updated till June 17, 2022		
* Changes in Directors not disclosed as the relevant fiscal year has not been completed.		

9 Status of implementation of project/ commencement of commercial production	
(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds					
(i) as disclosed in the offer document					
	(In Rs. Crore)				
Particulars	Total estimated amount/ expenditure	Amount already deployed as on June 30, 2021	Estimated utilisation from Net Proceeds	Estimated Deployment (Financial Year 2022)	Estimated Deployment (Financial Year 2023)
Funding capital expenditure requirements for expansion of our Dahej Manufacturing Facility	151.32	4.22	147.10	79.00	68.10
Funding capital expenditure requirements for upgradation at our R&D facility in Vadodara	23.97	0.00	23.97	13.00	10.97
General corporate purposes	26.21	0.00	36.21	36.21	
Total	201.50	4.22	207.28	128.21	79.07
(ii) Actual utilization					
	(In Rs. Crore)				
Particulars	As of March 31, 2021				
Funding capital expenditure requirements for expansion of our Dahej Manufacturing Facility	26.05				
Funding capital expenditure requirements for upgradation at our R&D facility in Vadodara	1.84				
General corporate purposes	36.21				
Total	64.10				
(iii) Reasons for deviation, if any					
	Not available				

11 Comments of monitoring agency, if applicable	
(a) Comments on use of funds	None
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
(c) Any other reservations expressed by the monitoring agency about the end use of funds	

12 Pricing Data

Issue Price (Rs.):	1083
Designated Stock Exchange:	BSE
Listing Date:	29-Jul-21

Price parameters	At close of listing day (Jul 29, 2021)	At close of 30th calendar day from listing day (Aug 27, 2021) ⁽¹⁾	At close of 90th calendar day from listing day (Oct 26, 2021) ⁽²⁾	As at the end of 1st FY after the listing of the issue (March 31, 2022) ⁽³⁾			As at the end of 2nd FY after the listing of the issue (March 31, 2023) ⁽³⁾⁽⁴⁾			As at the end of 3rd FY after the listing of the issue (March 31, 2024) ⁽³⁾⁽⁴⁾		
				Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange	2,310.25	2,085.60	2,546.60	2,307.70	2,975.55	2,000.75	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Sensex	52,653.07	56,124.72	61,350.26	58,568.51	62,245.43	52,260.82	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Sectoral Index ⁽⁵⁾	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available

- Note:
- (1) 30th calendar day shall be taken as listing date plus 29 calendar days.
 - (2) 90th calendar day shall be taken as listing date plus 89 calendar days.
 - (3) High and Low based on intra day prices.
 - (4) Pricing data not disclosed as the relevant fiscal year has not completed.
 - (5) There is no sectoral index

13 Basis for Issue Price

Accounting ratio	As disclosed in the offer document ⁽¹⁾	At the end of 1st FY (March 31, 2022)	At the end of 2nd FY (March 31, 2023) ⁽²⁾	At the end of 3rd FY (March 31, 2024) ⁽²⁾	
EPS	Issuer:				
	Basic	26.02	44.59	Not Available	
	Peer Group:				
	Aarti Industries Limited (Basic)	15.02	36.06	Not Available	
	Navin Fluorine International Limited (Basic)	52.03	53.12	Not Available	
	Alkyl Amines Chemicals Limited (Basic)	57.87	44.04	Not Available	
	Vinati Organics Limited (Basic)	26.20	33.73	Not Available	
	Fine Organics Industries Limited (Basic)	39.25	84.71	Not Available	
	Industry Avg:	Not Applicable	Not Applicable	Not Applicable	
	Issuer:	41.62	51.75	Not Available	
P/E	Peer Group:				
	Aarti Industries Limited	58.15	26.52	Not Available	
	Navin Fluorine International Limited	73.12	76.85	Not Available	
	Alkyl Amines Chemicals Limited	64.04	64.94	Not Available	
	Vinati Organics Limited	77.41	57.89	Not Available	
	Fine Organics Industries Limited	75.01	47.39	Not Available	
	Industry Avg:	69.55	54.72	Not Available	
	Issuer:	31.49	20.27	Not Available	
	RoNW (%)	Peer Group:			
		Aarti Industries Limited	15.23	22.10	Not Available
Navin Fluorine International Limited		15.76	14.27	Not Available	
Alkyl Amines Chemicals Limited		37.27	22.72	Not Available	
Vinati Organics Limited		17.45	18.96	Not Available	
Fine Organics Industries Limited		16.45	27.07	Not Available	
Industry Avg:		Not Applicable	Not Applicable	Not Applicable	
Issuer:		82.62	213.44	Not Available	
NAV per share		Peer Group:			
		Aarti Industries Limited	48.48	163.16	Not Available
	Navin Fluorine International Limited	33.01	372.17	Not Available	
	Alkyl Amines Chemicals Limited	15.53	193.80	Not Available	
	Vinati Organics Limited	15.02	177.85	Not Available	
	Fine Organics Industries Limited	23.86	312.85	Not Available	
	Industry Avg:	Not Applicable	Not Applicable	Not Applicable	

Notes:

- (1) Sourced from Prospectus.
- (2) Information not provided as the relevant fiscal year has not completed
- (3) Key ratios for the Company for 1st FY and 2nd FY stated above are calculated as follows:
 - (i) Basic and diluted earnings per Equity Share are based on the Annual Reports for the relevant years
 - (ii) P/E - Closing Market Price on BSE as of relevant fiscal year / EPS (diluted); Also disclosed EPS (basic) for the Issuer
 - (iii) RoNW - Net profit after tax attributable to the owners divided by net worth at the end of the relevant period
 - (iv) NAV per share - Net worth at the end of the relevant period divided by Total Equity Shares Outstanding as of fiscal year end

14 Any other material information

Date of disclosure to Designated Stock Exchange	Announcement
6-Aug-21	Tatva Chintan Pharma Chem Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2021 inter alia, to consider and approve 1. the unaudited Standalone financial results of the Company for the quarter ended 30 June 2021 and 2. the unaudited Consolidated financial results of the Company for the quarter ended 30 June 2021.
14-Aug-21	1. Copy of the Limited Review Report of the Statutory Auditors of the Company, M/s. NDJ & Co, Chartered Accountants, (Firm Registration No. 136345W), on the Un-audited Consolidated Financial Results; 2. Copy of the Un-audited Consolidated Financial Results of the Company for the quarter ended 30th June, 2021 of the Current Financial Year 2021-22; 3. Copy of the Limited Review Report of the Statutory Auditors of the Company, M/s. NDJ & Co, Chartered Accountants, (Firm Registration No. 136345W), on the Un-audited Standalone Financial Results; 4. Copy of the Un-audited Standalone Financial Results of the Company for the quarter ended 30th June, 2021 of the Current Financial Year 2021-22;
14-Aug-21	Intimation under Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 submitted
16-Aug-21	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed a copy of the Press Release on the financial results of the Company for the quarter ended 30 June 2021
16-Aug-21	Pursuant to regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we enclosed herewith copies newspaper publication of extract of unaudited financial results of the Company for the quarter ended on 30 June 2021, published in Financial Express (English edition) and Vadodara Samachar (Gujarati edition) on 15 August 2021.
24-Aug-21	Pursuant to Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation 2015, we hereby inform that Mr. Mahesh Tanna, Chief Financial Officer (CFO) of the Company has tendered his resignation from the post of Chief Financial Officer and Key Managerial Personnel (KMP) of the Company on 24th August, 2021. The Company has accepted his resignation and he will be relieved from the Company w.e.f 31st August, 2021 after closure of working hours.
1-Sep-21	The transcript of the earnings call held on 16 August 2021 post announcement of financial results of the company for the quarter ended 30 June 2021 .
6-Sep-21	Pursuant to Regulation 47 and Regulation 30 read with Schedule III Part A Para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find enclosed herewith the copies of newspaper advertisement published in English Language Newspaper published in 'Financial Express' and in Vernacular Newspaper in Vernacular Language 'Vadodara Samachar', on 06th September, 2021, in compliance with the Ministry of Corporate Affairs Circular No. 20/2020 dated 5 May 2020, intimating that the 25th Annual General Meeting (AGM) of members of the Company will be held on Wednesday, 29th September, 2021 at 4:00 p.m. (IST) through Video Conferencing (VC) / Other Audio Visual Means (OAVM) and information on related matters as required under the said MCA Circular.
6-Sep-21	Pursuant to Regulation 34(1)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We hereby enclosed the 25th Annual Report along with the Notice calling 25th Annual General Meeting of the Company scheduled to be held on Wednesday, 29 September, 2021 at 4:00 p.m. (IST) through Video Conferencing (VC) or Other Audio Visual Means (OAVM) (Comprising of Audited Standalone and Consolidated Financial Statements, Directors Report etc.) which is sent through electronic mode to the Members pursuant to the MCA Circular No. 20/2020 dated 5 May, 2020 read with Circular Nos. 14/2020 dated 8 April, 2020, 17/2020 dated 13 April, 2020 and 02/2021 dated 13 January, 2021 and SEBI Circular No. SEBI/NO/CFD/CMD1/CIR/P/2020/79 dated 12 May, 2020 and Circular No. SEBI/HO/CFD/CMD2/CIR/P/2021/11 dated 15 January, 2021 for the financial year ended 31 March, 2021
6-Sep-21	Pursuant to Regulation 30 read with clause 12 of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, We wish to inform you that the 25th Annual General Meeting (AGM) of the members of the Company will be held on Wednesday, 29 September, 2021, at 4:00 P.M. (IST) through Video Conferencing (VC) / Other Audio Visual Means (OAVM). Pursuant to provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended and Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Listing Regulations) the Company is providing to its members the facility to cast their vote by electronic means on all the resolutions set forth in the Notice.
23-Oct-21	We wish to inform that the Board of Directors of the Company at its meeting held today i.e., 23 October 2021, has approved the unaudited financial results of the Company (both standalone and consolidated) prepared in accordance with Indian Accounting Standards (IndAS) for the quarter and half year ended as on 30 September 2021. A copy of the said Financial Results together with Limited review report are enclosed herewith. The Board meeting commenced at 11.30 am and concluded at 3.00 pm.
23-Oct-21	Pursuant to Regulation 30(5) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, We are hereby disclosing the updated contact details of Key Managerial Personnel (KMP) who has been authorized by the Board of Directors at their meeting held on 23 October 2021 of the Company for the purpose of determining materiality of an event or information and of making disclosure of such material information to the stock exchange under these regulations are as stated below: Sr.No Name of KMP Designation Contact Details 01. Mr. Ajay Mansukhlal Patel Whole-time Director Email:ajay@tatvachintan.com Contact no:+91 75748 48533 / 34 02 Mr. Chintan Nitinumar Shah Managing Director Email:chintan@tatvachintan.com Contact no:+91 75748 48533 / 34 Kindly take the above disclosure on your records.

25-Oct-21	<p>Pursuant to regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we are enclosing herewith copies of newspaper publication of extract of unaudited financial results of the Company for the quarter ended on 30 September 2021, published in Financial Express (English edition) and Vadodara Samachar (Gujarati edition) on 24 October 2021.</p> <p>Kindly take the same on record and disseminate to the public at large</p>
27-Oct-21	<p>Pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith statement of deviation(s) or variation(s) in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended 30 September 2021 in the prescribed format. The same will be filed in XBRL mode separately.</p> <p>We confirm that, as at 30 September 2021, there has not been any deviation(s) or variation(s) in the utilization of net proceeds of IPO as mentioned in the objects stated in the Prospectus dated 22 July 2021.</p> <p>Monitoring agency report issued in this regard is being separately filed with the exchange.</p>
28-Oct-21	<p>Pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Monitoring agency report of the Company for the quarter ended 30 September 2021, issued by ICICI Bank Limited, appointed to monitor the utilization of proceeds of an Initial Public Offering (IPO) of the Company.</p> <p>Request you to please take the above on record.</p>
29-Oct-21	<p>Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on 25 October 2021 post announcement of financial results of the Company for the quarter and half year ended 30 September 2021. The Transcript has been uploaded on the Company's website www.tatvachintan.com.</p> <p>This is for your information and records.</p>
29-Oct-21	<p>Please find enclosed herewith, 'INVESTOR DECK' which contain general and financial information about the company.</p> <p>This information is being submitted for general purpose only and not under any statutory requirements.</p> <p>Kindly take note of the same. The same will also be available on the Company's website, "www.tatvachintan.com".</p> <p>This is for your information and records.</p>
29-Nov-21	<p>With reference to the above subject, we would like to inform you that as a part of future need, the Company has acquired an industrial land admeasuring 50,399.16 Sq. mtr at Dahej-III GIDC Estate, Bharuch, Gujarat, India. The above land has been acquired from internal accruals only & it will be used on need basis in future. The above disclosure is being made voluntarily for the record of Stock Exchanges.</p> <p>Kindly take the above disclosure on your records.</p>
3-Dec-21	<p>Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 as amended, we wish to inform that based on recommendation of the Nomination and Remuneration Committee (NRC), the Board of Director of the Company at its meeting held on Friday, 03 December 2021, has appointed Mr Ashok Bothra (Chartered Accountant) as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the Company with effect from 03 December 2021.</p> <p>The disclosure required under Regulation 30 of SEBI (LODR) Regulations, 2015 read with para A of Part A of Schedule III of the said regulations and read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 09 September 2015 is enclosed in Annexure-1</p>
5-Jan-22	<p>Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018</p>
7-Jan-22	<p>Tatva Chintan Pharma Chem Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/01/2022 inter alia, to consider and approve Pursuant to the Regulation 29 (1) (a) read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we hereby inform you that the Meeting of the Board of Directors of Tatva Chintan Pharma Chem Limited is scheduled to be held on Monday, 17 January, 2022, inter alia to: 1. Consider and approve the unaudited standalone financial results of the Company for the quarter/ nine months ended 31 December, 2021. 2. Consider and approve the unaudited consolidated financial results of the Company for the quarter /nine months ended 31 December 2021. Kindly take the above information on your record.</p>
11-Jan-22	<p>Statement Of Investor Complaints For The Quarter Ended December 2021 submitted</p>
13-Jan-22	<p>The Company had moved Adjudication Application before the office of ROC on suo-moto basis in April 2021. In the said Adjudication Application, We have received an order from the office of ROC with a penalty on the Company, its three directors and two key managerial personnel. The details of the same are: During RHP/ IPO, Company has found that it has not complied with the section 42 of the Companies Act, 2013 w.r.t. opening of separate bank account for depositing the share application money in the year 2015. Accordingly, the same was disclosed in RHP (Refer point no: 28 on Pg. No. 36 and 37). Adjudication Application was submitted on suo-moto basis before the office of ROC in April 2021. Company being an aggrieved party, has decided to appeal against the said order before office of Regional Director, NWR, MCA.</p>
17-Jan-22	<p>Outcome of the Board Meeting held on January 17, 2022 submitted</p>
17-Jan-22	<p>Pursuant to the provisions of Regulation 30 of Securities and Exchange Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Ms. Apurva Dubey has tendered her resignation today i.e. January 17, 2022 from the post of Company Secretary and Compliance Officer (Key Managerial Personnel) of Tatva Chintan Pharma Chem Limited. She will continue to work with Tatva Chintan Pharma Chem Limited as Assistant Company Secretary of the Company. The Company has accepted her resignation and she shall cease to be the Company Secretary and Compliance Officer (Key Managerial Personnel) with effect from close of working hours of January 17, 2022. However, she will continue to work with Tatva Chintan Pharma Chem Limited as mentioned above. We request you to kindly take the above on record and oblige.</p>
17-Jan-22	<p>Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Press Release on the financial results of the Company for the quarter and nine months ended December 31, 2021.</p>
18-Jan-22	<p>Pursuant to regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we are enclosing herewith copies of newspaper publication of extract of unaudited financial results of the Company for the quarter and nine months ended on December 31, 2021, published in Financial Express (English edition) and Vadodara Samachar (Gujarati edition) on January 18, 2022. Kindly take the same on record and disseminate to the public at large.</p>
18-Jan-22	<p>We hereby enclosed Investor Presentation for the quarter and nine months ended December 31, 2021. The same will be uploaded on the Company's website.</p>
20-Jan-22	<p>Pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith statement of deviation(s) or variation(s) in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended December 31, 2021 in the prescribed format. The same will be filed in XBRL mode separately. We confirm that, as at December 31, 2021, there has not been any deviation(s) or variation(s) in the utilization of net proceeds of IPO as mentioned in the objects stated in the Prospectus dated July 22, 2021. Monitoring agency report issued in this regard is being separately filed with the exchange. Kindly take the above information on your record.</p>
20-Jan-22	<p>Pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Monitoring agency report of the Company for the quarter ended December 31, 2021, issued by ICICI Bank Limited, appointed to monitor the utilization of proceeds of an Initial Public Offering (IPO) of the Company. Kindly take the above information on your record.</p>
21-Jan-22	<p>Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on January 18, 2022 post announcement of financial results of the Company for the quarter and nine months ended December 31, 2021. The same will be uploaded on the Company's website. This is for your information and records.</p>
24-Jan-22	<p>With reference to above mentioned subject, we would like to inform you that there is typographical error in point no. 6 of notes to Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended on December 31, 2021. The respective correction does not have any impact on financial figure/results/XBRL.</p>
1-Feb-22	<p>Pursuant to Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we would like to inform you that we have revamped our website i.e. www.tatvachintan.com, which is more user and Investor Friendly. Request you to please take the above on record.</p>
30-Mar-22	<p>Pursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended and Company's code on prohibition of insider trading, the "Trading Window" for dealing in the securities of the Company shall remain closed for all Designated Persons and their immediate relatives from Friday, 01 April 2022 till the completion of 48 hours after the Audited Financial Results of the Company for the Fourth Quarter and Financial Year ending 31 March 2022 become Generally Available Information. Accordingly, all Designated Persons and their immediate relatives of the Company have been advised not to trade in the securities of the Company during the aforesaid period of Closure of Trading Window. Kindly take the above information on your record.</p>
6-Apr-22	<p>Compliance Certificate pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018</p>
7-Apr-22	<p>Statement Of Investor Complaints For The Quarter Ended March 2022</p>
7-Apr-22	<p>Compliance certificate pursuant to Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the year ended 31 March 2022.</p>
9-Apr-22	<p>Pursuant to Regulation 40(9) & (10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Certificate obtained from M/s. TNT & Associates, Practicing Company Secretaries for the year ended on 31 March 2022. Kindly take the above information on your record.</p>
15-Apr-22	<p>Tatva Chintan Pharma Chem Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/04/2022 inter alia, to consider and approve 1. consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31 March 2022; 2. consider and recommend a final dividend, if any, on the equity shares of the Company for the financial year ended 31 March 2022, subject to approval of the shareholders at the ensuing Annual General Meeting of the Company. Further, in accordance with the Company's Code of Conduct for Prohibition of Insider Trading, the Company has intimated its "designated persons" regarding the closure of the Trading Window for trading in the Company's equity shares from 01 April 2022 till the expiry of 48 hours from the date the said financial results are made public. The above information is also being made available on the website of the Company at www.tatvachintan.com. Kindly take above intimation on your record and oblige.</p>
16-Apr-22	<p>Tatva Chintan Pharma Chem Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on April 25, 2022, inter alia, to:</p> <ol style="list-style-type: none"> 1. consider and approve and take on record the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended March 31, 2022. 2. consider and recommend a final dividend, if any, on the equity shares of the Company for the financial year ended March 31, 2022, subject to approval of the shareholders at the ensuing Annual General Meeting of the Company. <p>Further, in accordance with the Company's Code of Conduct for Prohibition of Insider Trading, the Company has intimated its "designated persons" regarding the closure of the Trading Window for trading in the Company's equity shares from April 01, 2022 till the expiry of 48 hours from the date the said financial results are made public.</p>
20-Apr-22	<p>Format of Initial Disclosure to be made by an entity identified as a Large Corporate submitted</p>
25-Apr-22	<p>Outcome Of The Board Meeting Held On 25.04.2022 submitted</p>
25-Apr-22	<p>Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended on 31 March 2022</p>
25-Apr-22	<p>The Board Recommended a Final Dividend of Rs. 2/- (20%) per equity share of Rs. 10/- each fully paid (subject to deduction of tax, if any) on the equity share capital of Rs. 22,16,50,620/- (2,21,65,06,200/-) (2,21,65,06,200/-) equity shares of Rs. 10/- each) for the financial year 2021-22. This shall be paid subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.</p>
25-Apr-22	<p>Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Press Release on financial results of the Company for the quarter and year ended 31 March 2022. The above information is also being made available on the website of the Company at www.tatvachintan.com. This is for your information and records.</p>
25-Apr-22	<p>Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed Investor Presentation for the quarter and year ended 31 March 2022. The above information is also being made available on the website of the Company at www.tatvachintan.com. This is for your information and records.</p>
25-Apr-22	<p>Pursuant to Regulation 46(2)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform the exchanges that the recording of the Earnings Call held on Monday, 25 April 2022 at 5:00 pm IST is available on the website of the Company. The recording can be accessed from the following link: https://www.tatvachintan.com/wp-content/uploads/2022/04/Audio-Link.mp3</p>
26-Apr-22	<p>Pursuant to regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find enclosed herewith copies of newspaper advertisement pertaining to extract of financial results of the Company for the quarter and year ended 31 March 2022, published in Financial Express (English edition) and Vadodara Samachar (Gujarati edition) on 26 April 2022. The above information will also be hosted on Company's website of at www.tatvachintan.com. Kindly take the same on record and disseminate to the public at large.</p>

28-Apr-22	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith the transcript of the earnings call held on 25 April 2022 post announcement of financial results of the Company for the quarter and year ended 31 March 2022. The above information will also be hosted on Company's website of at www.tatvachintan.com . This is for your information and records.
30-Apr-22	Pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed herewith statement of deviation(s) or variation(s) in utilization of funds raised through Initial Public Offering (IPO) for the quarter ended 31 March 2022 in the prescribed format. The same will be filed in XBRL mode separately. We confirm that, as at 31 March 2022, there has not been any deviation(s) or variation(s) in the utilization of net proceeds of IPO as mentioned in the objects stated in the Prospectus dated 22 July 2021. Report issued by Monitoring agency report is being separately filed with the exchange. The above information is also being made available on the website of the Company at www.tatvachintan.com . Kindly take the above information on your record.
30-Apr-22	Pursuant to Regulation 32(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Monitoring agency report of the Company for the quarter ended 31 March 2022, issued by ICICI Bank Limited, appointed to monitor the utilization of proceeds of an Initial Public Offering (IPO) of the Company. The above information is also being made available on the website of the Company at www.tatvachintan.com . Kindly take the above information on your record.
4-May-22	Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular no. CIR/CFD/CMD1/27/2019 dated February 8, 2019, please find enclosed herewith copy of the Annual Secretarial Compliance Report of the Company issued by M/s. TNT & Associates, Practicing Company Secretaries, Vadodara, Gujarat, India for the financial year ended 31 March, 2022. The above information shall be uploaded on the website of the Company at www.tatvachintan.com . Kindly take the above information on your record.
11-May-22	Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
20-May-22	Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions for the half year ended 31 March 2022. The above information shall be uploaded on the website of the Company at www.tatvachintan.com . Kindly take the same on your record.

Notes:
The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable. For further updates and information, please refer to the website of the Stock Exchanges i.e. www.bseindia.com and/or www.nseindia.com.

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by JM Financial Limited ("JM Financial") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012. This information is gathered from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and/or the National Stock Exchange of India Limited ("NSE" and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information. Notwithstanding the above, JM Financial does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither JM Financial nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement.